semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Differentiated Thyroid Cancer Signed and dated informed consent 2. Histological documentation of Differentiated Thyroid Cancer ,With measurable disease (using 3. ECOG PS:0-1,Life expectancy of more than 6 months 4. Subjects must be 131I-refractory / resistant as defined by at least one of the following Lesions that do not demonstrate iodine uptake on any radioiodine scan Cumulative activity of 131I of >600 mCi or 22 gigabequerels (GBq) Lesion that demonstrate iodine uptake on any radioiodine scan,but has progressed by 1.1 within 18 months of 131I therapy 5. main organs function is normal  Prior treatment with Anlotinib or VEGFR-targeted therapies(such as Vandetanib,Cabozantinib,Lenvatinib,Sunitinib,Sorafenib etc.) 2. Subjects received radiotherapy external exposure or 131I within 3 months prior to the first dose of study drug or plan to be received any anti-cancer treatment during study 3. Patients suffering from other malignancies currently or within 5 years, except for cured cervical carcinoma in situ, non-melanoma skin cancers and superficial bladder cancer [ Ta (non-invasive carcinoma), Tis (carcinoma in situ) and T1 (carcinoma invasion into lamina propria) ] 4. CTCAE(4.0) Grade 1 or higher non-remission toxicity induced by any other previous treatments，excluding alopecia and Grade 2 or lower neurotoxicity induced by oxaliplatin 5. Patients with factors that could affect oral medication (such as dysphagia etc.) 6. Patients with pleural effusion or ascites, causing respiratory syndrome (CTCAE Grade 2 or higher dyspnea [Grade 2 dyspnea refers to Shortness of breath with a small amount of activities, affecting Instrumental activities of daily life]) 7. Patients underwent major surgical treatment，open biopsy or significant traumatic injury within 28 days prior to assignment
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Atopic Dermatitis Key 1. Non-immunocompromised male or non-pregnant, non-lactating female, 18 years of age or older with a clinical diagnosis of moderate to severe AD. 2. Have confirmed diagnosis of atopic dermatitis for at least 3 months using the diagnostic features as described by Hanifin and Rajka 3. Have an IGA score of 3 (moderate) or 4 (severe). 4. Have an affected Body Surface Area (BSA) of at least 20% at baseline. 5. Treated with a bland emollient for at least 7 days. Key  Active cutaneous bacterial or viral infection in any treatment area at baseline. 2. Sunburn, extensive scarring, or pigmented lesion(s) in any treatment area at baseline. 3. History of confounding skin conditions, e.g., psoriasis, rosacea, erythroderma, or ichthyosis. 4. History or presence of Netherton's Syndrome, immunological deficiencies or diseases, HIV, diabetes, malignancy, serious active or recurrent infection, clinically significant severe renal insufficiency or severe hepatic disorders. 5. Known allergy or hypersensitivity to tacrolimus or any other component of the Study products
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Trismus Edema Pain necessity of bilateral impacted third molar removal with similar dental arch positioning and similar surgical difficulty  Compromised Systemic Health status, Neurologic and/or mental disorders, local infection history, anti-inflammatory or analgesic use for the last 15 days, tabagism, ethylism, pregnancy
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 0.167-999.0,  Defective Mineralization IInclusion Informed consent will be obtained from the patient or the parents before any study related procedures Patients of both genders older than 2 month The patient has a diagnosis of Hypophosphatasia disease or a high-grade suspicion for Hypophosphatasia disease High-grade suspicion present, if one or more are valid Positive family anamnesis for Hypophosphatasia disease Frequent fractures Bone pain Tooth loss Osteopenia/Osteoporosis  No Informed consent from the patient or the parents before any study related procedures Patients of both gender younger than 2 month No diagnosis of Hypophosphatasia disease or no valid for profound suspicion of Hypophosphatasia disease
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 2.0-21.0,  Simple Bone Cyst Arm 1 Simple Bone Cyst Patients 1. Patients ≥ 2 and ≤ 21 years 2. Patients with a diagnosis of simple bone cyst located in a long bone confirmed by imaging within 3 months prior to registration 3. All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines  Patients with implants to stabilize the bone where the cyst is located. 2. Patients with bone disease (i.e. osteogenesis imperfecta, cancer, osteoporosis, Paget's disease) 3. Patients who are pregnant or breastfeeding 4. Patients with a simple bone cyst crossing the growth plate Arm 2 Healthy Controls 1. Patients ≥ 2 and ≤ 21 years 2. All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines Patients with bone disease (i.e. osteogenesis imperfecta, cancer, osteoporosis, Paget's disease) 2. Patients receiving any bone-modifying agents (i.e. steroids, bisphosphanates, etc.) 3. Patients who are pregnant or breastfeeding Arm 3 Fracture patients 1. Patients ≥ 2 and ≤ 21 years 2. Patients who have undergone any type of casting or surgical treatment for their fracture 3. All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines Patients with bone disease (i.e. osteogenesis imperfecta, cancer, osteoporosis, Paget's disease) 2. Patients receiving any bone-modifying agents (i.e. steroids, bisphosphanates, etc.) 3. Patients who are pregnant or breastfeeding
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Lung Cancer Age between 18 and 70 years of age, male or female 2. histologically or cytologically confirmed stage IIIB or IV lung cancer at diagnosis 3. no evidence of bone metastatic lesions was radiographically confirmed by bone scintigraphy 4. life expectancy of ≥6 months 5. adequate renal, hematologic, and hepatic 6. Eastern Cooperative Oncology Group(ECOG) performance status≤2 7. All patients provided written informed consent  Treatment with other bisphosphonates 2. Presence of brain metastases 3. Be allergic to ZOL 4. attending other unlisted drug clinical trials,currently
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Neoplasms, Connective and Soft Tissue Bone Neoplasms Must have a diagnosis or presumed diagnosis of bone or soft tissue tumor as defined by the WHO classification of tumors of soft tissue and bone (4th ed.) Patient, or his/her designated power of attorney, must be able to understand and approve of the consent to participate  Prisoners are excluded from participation in the Registry
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-70.0,  Osteoarthritis Bilateral Total Knee Arthroplasty Age ≤ 70 years Undergoing bilateral, simultaneous, primary knee replacements  neurological, vascular or cardiac problems that limit function unstable orthopedic conditions that limit functional performance previous history of inflammatory arthritis or other inflammatory systemic conditions previous history of deep vein thrombosis in either lower extremity lymphedema or other conditions that lead to lower extremity edema that may influence the outcomes of the study
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Kidney Diseases Patients who are regularly (3 times a week) on dialysis in the Maria-Hilf-Clinic or healthy subjects Male or Female at the age of at least 18 years Patients who will be admitted to the clinics of the University Hospital RWTH Aachen or of the Maria-Hilf-Clinic Mönchengladbach or healthy subjects written informed consent form Subjects who are contractually capable and mentally able to understand and follow the instructions of the study personnel  age < 18 years subjects who are unwilling or not able to consent pregnant or lactating women subject has been committed to an institution by legal or regulatory order dependency or working relationship with the investigator participation in a parallel interventional clinical study Hb-value < 10 g/dl
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 10.0-999.0,  Osteoid Osteoma Age superior or equal to 10 years Patient with a typical osteoid osteoma diagnosed on clinical and radiological (MRI and scanner), validated by a binomial clinician / radiologist OO never treated or in treatment failure, or recurrent OO OO percutaneously accessible Pain intensity is superior or equal to 40 mm on a VAS at visit Written informed consent signed by the patient or his representative (for minors, agreement of the child and signature of the two mandatory parents) Patient affiliated to the social security  Patients with other diseases or receiving treatment that may impact on bone tissue or its metabolism Patients suffering from renal failure (i.e. lower than 60 ml/min according to the Cowcroft equation) Patients with severe hepatocellular insufficiency (TP<50%) Patients with a history of iritis or uveitis Patient with untreated rickets or osteomalacia Patient with untreated dental infection or planed dental surgery during the study period Patient with untreated infection of the external auditory canal (ex: furuncle, eczema superinfection) Patient already treated by bisphosphonates Patients with hypersensitivity to the active substance, to other bisphosphonates or to any of the excipients (List of excipients: mannitol (E421), sodium citrate (E331), water for injections) Patient enrolled in another biomedical research protocol and during the whole study
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  HIV Infection Diabetes Mellitus Type 2 Obesity Overweight Metabolic Syndrome HIV controlled on therapy for at least 12 weeks Viral load < 200 copies BMI >27 to 45 Diagnosis of DM type 2 with A1-C >7 to 15 Participants must be willing to comply with all study related procedures  Personal or family history of pancreatitis Medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2) Gastroparesis Allergy to liraglutide or any of the active ingredients in liraglutide or other GLP-1 analogue Weight loss drugs other than metformin Type 1 diabetes mellitus or diabetic ketoacidosis Known major cognitive deficit dementia, history of head trauma with loss of consciousness >30 min, history of stroke, current central nervous system (CNS) disorder such as seizures or opportunistic CNS infection Renal insufficiency defined as creatinine clearance < 60 mL/min Active opportunistic infections Pregnancy or breastfeeding
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 1.0-60.0,  Bone Defect Bone Nonunion the patients with bone defect and bone nonunion caused by tumor or trauma the length of bone defect in long diaphysis is more than 4cm or more than half of the shaft diameter the size of bone defect is more than 5cmx5cm the patients are unable to use autologous bone graft or other treatments the patients request to use the treatment of tissue-engineered bone Supportive family with willingness to participate in completing questionnaires  Patients with serious diseases such as hemorrhagic disorders, infection, tumor, contagion and so on Patients who are pregnant Patients with serious abnormal cardiopulmonary function Patients disagree to use the tissue-engineered bone Patients are older than 60 years Patients who are regarded to be unqualified by investigator
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Varicose Vein of Lower Limbs Age equal to or greater than 18 years patients with varicose veins with edema CEAP classification C3EpAsPr Great saphenous vein incompetence, segmental and total, with diameter from 6 to 10 mm in proximal thigh, 3 cm from the saphenous femoral junction measured by ultrasound  Allergy to the sclerosant substance acute deep vein thrombosis or pulmonary thromboembolism local infection in the area of sclerotherapy or severe systemic infection prolonged immobilisation symptomatic patent foramen ovale pregnancy peripheral arterial occlusive disease short saphenous vein incompetence association refusal to sign the consent form nonadherence to outpatient treatment